1.	Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: NCI, Other Protocol IDs: CDR0000065424, UCCRC-9018, UCCRC-8381, NCI-G97-1162, NCT00002952
2.	Phase I/II Study of Immunization With MAGE-3 Plus Immunological Adjuvant SB AS-2 in HLA Class I Patients With MAGE-3 Positive Refractory Malignant Tumors (Summary Last Modified 12/1999) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Protocol IDs: EORTC-18972-13971/LUD97-002
3.	Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-11447A, NCI-1330, NCT00064168, 1330
4.	Phase II Pilot Study of a Multipeptide (gp100 Antigen, MAGE-3, and Tyrosinase Peptide) Melanoma Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Patients With Resected Stage IIC, III, or IV Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: LAC-USC-10M033, LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189
5.	Melanoma Vaccine With Peptides and Leuprolide Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 2004-0502, NCT00254397
6.	Phase I Study of Dendritic Cell Immunotherapy in Patients With Metastatic Melanoma (Summary Last Modified 09/2000) Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: NCI Protocol IDs: BAYUMC-098004, NCI-T98-0054, NCT00003792, T98-0054